0001411690-20-000017 | 10-Q | XBRL Viewer

Print Document View Excel Document

Cover - shares	6 Months Ended
Cover - shares	Jun. 30, 2020	Aug. 12, 2020
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2020
Document Transition Report	false
Entity File Number	001-38613
Entity Registrant Name	Bionano Genomics, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	26-1756290
Entity Address, Address Line One	9540 Towne Centre Drive, Suite 100
Entity Address, City or Town	San Diego
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92121
City Area Code	858
Local Phone Number	888-7600
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding (in shares)		138,480,045
Amendment Flag	false
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q2
Entity Central Index Key	0001411690
Current Fiscal Year End Date	--12-31
Common Stock
Document Information [Line Items]
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Trading Symbol	BNGO
Security Exchange Name	NASDAQ
Warrant
Document Information [Line Items]
Title of 12(b) Security	Warrants to purchase Common Stock
Trading Symbol	BNGOW
Security Exchange Name	NASDAQ

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 17,194	$ 17,311
Accounts receivable, net	3,249	6,334
Inventory, net	3,290	3,444
Prepaid expenses and other current assets	921	1,169
Total current assets	24,654	28,258
Property and equipment, net	2,550	1,950
Total assets	27,204	30,208
Current liabilities:
Accounts payable	2,850	2,699
Accrued expenses	2,431	3,225
Contract liabilities	289	358
Current portion of long-term debt	13,938	20,085
Total current liabilities	19,508	26,367
Long-term debt, net of current portion	1,775	0
Long-term contract liabilities	84	183
Other non-current liabilities	0	44
Total liabilities	21,367	26,594
Commitments and contingencies
Stockholders’ equity:
Common stock, $0.0001 par value, 200,000,000 and 200,000,000 shares authorized at June 30, 2020 and December 31, 2019, respectively; 91,975,000 and 34,274,000 shares issued and outstanding at June 30, 2020 and December 31, 2019, respectively	9	3
Additional paid-in capital	126,989	106,188
Accumulated deficit	(121,161)	(102,577)
Total stockholders’ equity	5,837	3,614
Total liabilities and stockholders’ equity	$ 27,204	$ 30,208

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Common stock, par value (in USD per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, shares issued (in shares)	91,975,000	34,274,000
Common stock, shares outstanding (in shares)	91,975,000	34,274,000

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Revenue:
Total revenue	$ 1,182	$ 2,175	$ 2,318	$ 4,027
Cost of revenue:
Total cost of revenue	603	1,555	1,459	2,702
Operating expenses:
Research and development	2,401	2,408	5,075	4,508
Selling, general and administrative	5,613	5,056	12,981	9,846
Total operating expenses	8,014	7,464	18,056	14,354
Loss from operations	(7,435)	(6,844)	(17,197)	(13,029)
Other expenses:
Interest expense	(561)	(645)	(1,322)	(959)
Loss on debt extinguishment	0	0	0	(1,333)
Other expenses	(73)	(171)	(55)	(186)
Total other expenses	(634)	(816)	(1,377)	(2,478)
Loss before income taxes	(8,069)	(7,660)	(18,574)	(15,507)
Provision for income taxes	(5)	(5)	(10)	(9)
Net loss	$ (8,074)	$ (7,665)	$ (18,584)	$ (15,516)
Net loss per share, basic and diluted (USD per share)	$ (0.09)	$ (0.71)	$ (0.29)	$ (1.47)
Weighted-average common shares outstanding basic and diluted (shares)	90,907,000	10,860,000	63,238,000	10,542,000
Product revenue
Revenue:
Total revenue	$ 940	$ 2,021	$ 1,923	$ 3,708
Cost of revenue:
Total cost of revenue	515	1,525	1,289	2,645
Service and other revenue
Revenue:
Total revenue	242	154	395	319
Cost of revenue:
Total cost of revenue	$ 88	$ 30	$ 170	$ 57

Condensed Consolidated Statements of Stockholders’ Equity (Deficit) - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit
Beginning Balance (shares) at Dec. 31, 2018		10,055
Beginning Balance at Dec. 31, 2018	$ 10,137	$ 1	$ 82,898	$ (72,762)
Equity
Stock option exercises (in shares)		42
Stock option exercises	54		54
Stock-based compensation expense	289		289
Issue common stock, net of issuance costs (shares)		748
Issue common stock, net of issuance costs	2,410		2,410
Issue warrants for debt	630		630
Issue stock for debt	202		202
Net loss	(7,852)			(7,852)
Ending Balance (shares) at Mar. 31, 2019		10,845
Ending Balance at Mar. 31, 2019	5,870	$ 1	86,483	(80,614)
Beginning Balance (shares) at Dec. 31, 2018		10,055
Beginning Balance at Dec. 31, 2018	10,137	$ 1	82,898	(72,762)
Equity
Net loss	(15,516)
Ending Balance (shares) at Jun. 30, 2019		10,898
Ending Balance at Jun. 30, 2019	(1,345)	$ 1	86,933	(88,279)
Beginning Balance (shares) at Mar. 31, 2019		10,845
Beginning Balance at Mar. 31, 2019	5,870	$ 1	86,483	(80,614)
Equity
Stock option exercises (in shares)		9
Stock option exercises	11		11
Stock-based compensation expense	336		336
Issue stock for employee stock purchase plan (shares)		44
Issue stock for employee stock purchase plan	103		103
Net loss	(7,665)			(7,665)
Ending Balance (shares) at Jun. 30, 2019		10,898
Ending Balance at Jun. 30, 2019	(1,345)	$ 1	86,933	(88,279)
Equity
Stock-based compensation expense	364		364
Net loss	(6,398)			(6,398)
Ending Balance (shares) at Sep. 30, 2019		10,898
Ending Balance at Sep. 30, 2019	(7,379)	$ 1	87,297	(94,677)
Equity
Stock-based compensation expense	357		357
Issue common stock, net of issuance costs (shares)		11,081
Issue common stock, net of issuance costs	8,550	$ 1	8,549
Issue stock for covenant waiver (shares)		573
Issue stock for covenant waiver	504		504
Issue stock for employee stock purchase plan (shares)		44
Issue stock for employee stock purchase plan	39		39
Issue stock for warrant exercises (shares)		11,678
Issue stock for warrant exercises	9,397	$ 1	9,396
Reduce warrant exercise price for covenant waiver	46		46
Net loss	(7,900)			(7,900)
Ending Balance (shares) at Dec. 31, 2019		34,274
Ending Balance at Dec. 31, 2019	3,614	$ 3	106,188	(102,577)
Equity
Stock-based compensation expense	328		328
Issue stock for warrant exercises (shares)		3,478
Issue stock for warrant exercises	2,355		2,355
Net loss	(10,510)			(10,510)
Ending Balance (shares) at Mar. 31, 2020		37,752
Ending Balance at Mar. 31, 2020	(4,213)	$ 3	108,871	(113,087)
Beginning Balance (shares) at Dec. 31, 2019		34,274
Beginning Balance at Dec. 31, 2019	$ 3,614	$ 3	106,188	(102,577)
Equity
Stock option exercises (in shares)	0
Net loss	$ (18,584)
Ending Balance (shares) at Jun. 30, 2020		91,975
Ending Balance at Jun. 30, 2020	5,837	$ 9	126,989	(121,161)
Beginning Balance (shares) at Mar. 31, 2020		37,752
Beginning Balance at Mar. 31, 2020	(4,213)	$ 3	108,871	(113,087)
Equity
Stock-based compensation expense	328		328
Issue common stock, net of issuance costs (shares)		16,896
Issue common stock, net of issuance costs	16,366	$ 2	16,364
Issue stock for covenant waiver (shares)		873
Issue stock for covenant waiver	300		300
Issue stock for employee stock purchase plan (shares)		44
Issue stock for employee stock purchase plan	21		21
Issue stock for warrant exercises (shares)		36,410
Issue stock for warrant exercises	1,109	$ 4	1,105
Net loss	(8,074)			(8,074)
Ending Balance (shares) at Jun. 30, 2020		91,975
Ending Balance at Jun. 30, 2020	$ 5,837	$ 9	$ 126,989	$ (121,161)

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Operating activities:
Net loss	$ (18,584)	$ (15,516)
Adjustments to reconcile net loss to net cash used by operating activities:
Depreciation and amortization expense	591	537
Non-cash interest	651	296
Stock-based compensation	656	625
Provision for bad debt expense	1,290	0
Loss on debt extinguishment	0	1,333
Employee stock purchase plan compensation	0	103
Changes in operating assets and liabilities:
Accounts receivable	1,795	(469)
Inventory	(1,037)	(1,954)
Prepaid expenses and other current assets	244	288
Accounts payable	150	2,257
Accrued expenses and contract liabilities	(1,006)	(368)
Net cash used in operating activities	(15,250)	(12,868)
Investing Activities:
Purchases of property and equipment	0	(30)
Net cash used in investing activities	0	(30)
Financing activities:
Proceeds from issuance of term debt, net of issuance costs	0	19,207
Repayment of term-loan debt	(5,000)	(10,812)
Proceeds from PPP Loan	1,775	0
Proceeds from borrowing from line of credit	760	1,106
Repayments of borrowing from line of credit	(2,258)	(306)
Proceeds from sale of common stock, net of offering costs	16,366	2,410
Proceeds from sale of common stock under employee stock purchase plan	21	0
Proceeds from warrant and option exercises	3,469	65
Net cash provided by financing activities	15,133	11,670
Net decrease in cash and cash equivalents	(117)	(1,228)
Cash and cash equivalents at beginning of period	17,311	16,523
Cash and cash equivalents at end of period	17,194	15,295
Supplemental cash flow disclosures:
Cash paid for interest	715	245
Supplemental disclosure of non-cash investing and financing activities:
Property and equipment costs incurred but not paid included in accounts payable and accrued expenses	0	9
Fair value of warrants issued with debt	0	630
Transfer of instruments and servers from inventory to property and equipment	1,191	0
Issue common stock for covenant waiver	300
Fair value of stock issued with debt	$ 0	$ 202

Organization and Basis of Presentation	6 Months Ended
Organization and Basis of Presentation	Jun. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Basis of Presentation	Organization and Basis of Presentation Description of Business Bionano Genomics, Inc. (collectively, with its consolidated subsidiary, the “Company”) is a life sciences instrumentation company in the genome analysis space. The Company currently develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. Basis of Presentation The accompanying financial information has been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission for interim reporting purposes. The condensed consolidated financial statements are unaudited. The unaudited condensed consolidated financial statements reflect, in the opinion of the Company's management, all adjustments, consisting of only normal recurring adjustments, necessary for a fair presentation of financial position, results of operations, changes in equity, and comprehensive loss and cash flows for each period presented in accordance with United States generally accepted accounting principles (“U.S. GAAP”). All intercompany transactions and balances have been eliminated. These interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2019. Certain prior year numbers were reclassified to conform with current year presentation. Such reclassification had no impact on the previously reported results of operations. Going Concern The Company is required to perform an analysis regarding its ability to continue as a going concern. The Company must evaluate whether there are conditions and events that raise substantial doubt about the Company’s ability to continue as a going concern and to meet its obligations as they become due within one year after the date that the financial statements are issued. If the Company concludes that substantial doubt is raised, the Company is also required to consider whether its plans alleviate that doubt. The Company has experienced recurring net losses from operations, negative cash flows from operating activities, financial covenant breaches, and significant accumulated deficit since its inception and expects to continue to incur net losses into the foreseeable future. The Company had an accumulated deficit of $121.2 million as of June 30, 2020. The Company had cash and cash equivalents of $17.2 million as of June 30, 2020. Management expects operating losses and negative cash flows to continue for at least the next year as the Company continues to incur costs related to research and commercialization efforts. Management has prepared cash flow forecasts which indicate that based on the Company’s expected operating losses, negative cash flows and debt obligations, there is substantial doubt about the Company’s ability to continue as a going concern within twelve months after the date these financial statements are issued. COVID-19 continues to spread in the United States and globally and as a result the Company is subject to additional risks and uncertainties. The degree to which the Company's business will be affected by the COVID-19 pandemic is highly uncertain. The negative effects of COVID-19 could continue to have a material impact on the Company’s financial results. To comply with various applicable guidelines and legal requirements in the jurisdictions in which the Company operates, the Company has temporarily reduced its business operations in response to stay-at-home orders, travel restrictions and other social distancing measures. The Company’s manufacturing partners, suppliers, and customers, have implemented similar operational reductions. This overall reduction in activity has contributed to a decrease in sales which has negatively impacted the Company’s first and second quarter 2020 financial results. Future effects of COVID-19 are unknown and the Company’s financial results may continue to be negatively affected in the future. There may be long-term negative effects of the COVID-19 pandemic, even after it has subsided. Specifically, product demand may be reduced due to an economic recession, a decrease in corporate capital expenditures, prolonged unemployment, reduction in consumer confidence, or any similar negative economic condition. These negative effects could have a material impact on the Company’s operations, business, earnings, and liquidity. The Company’s ability to continue as a going concern is dependent upon its ability to raise additional funding. The Company will need to raise additional capital through equity offerings or debt financings to fulfill its operating and capital requirements for at least 12 months and to maintain compliance with certain financial covenants in the Innovatus LSA (as defined below). To raise such additional capital, the Company may pursue equity or debt financings, strategic collaborations, licensing arrangements, asset sales, or other arrangements. However, the Company may not be able to secure such financing in a timely manner or on favorable terms, if at all, and may not be able to comply with current covenants. Furthermore, if the Company issues equity securities to raise additional funds, its existing stockholders may experience dilution, and the new equity securities may have rights, preferences and privileges senior to those of the Company’s existing stockholders. If the Company raises additional funds through collaboration, licensing or other similar arrangements, it may be necessary to relinquish valuable rights to its products or proprietary technologies or grant licenses on terms that are not favorable to the Company. If the Company does not have or is not able to obtain sufficient funds, it may have to reduce commercialization efforts or delay its development of new products. The Company also may have to reduce marketing, customer support or other resources devoted to its products or cease operations. As a result, the aforementioned conditions, among others, raise substantial doubt about the Company's ability to continue as a going concern within one year after the date these financial statements are issued. Such financial statements have been prepared on a going concern basis, which contemplates the realization of assets and settlement of liabilities in the normal course of business, and do not include any adjustments to reflect the outcome of this uncertainty. As a publicly-traded company listed on The Nasdaq Stock Market LLC ("Nasdaq"), the Company is required to comply with rules and regulations issued by Nasdaq. If the Company is not able to comply with such rules and regulations, which it has not met from time-to-time since the Company's initial public offering in August 2018, the Company may not be able to maintain its Nasdaq listing. In April 2020, we received a Notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) advising us that for 30 consecutive trading days preceding the date of the Notice, the bid price of our common stock had closed below the $1.00 per share minimum required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Notice has no effect on the listing of our common stock at this time, and our common stock continues to trade on The Nasdaq Capital Market under the symbol “BNGO.” We intend to monitor the closing bid price of our common stock and may, if appropriate, consider implementing available options to regain compliance with the Minimum Bid Price Requirement. Significant Accounting Policies During the six months ended June 30, 2020, there were no changes to the Company's significant accounting policies as described in the Company's Annual Report on Form 10-K for the year ended December 31, 2019. Recently Issued But Not Yet Adopted Accounting Pronouncements In April 2012, the Jump-Start Our Business Startups Act (the “JOBS Act”) was signed into law. The JOBS Act contains provisions that, among other things, reduce certain reporting requirements for an emerging growth company. As an emerging growth company, the Company may elect to adopt new or revised accounting standards when they become effective for non-public companies, which typically is later than when public companies must adopt the standards. The Company has elected to take advantage of the extended transition period afforded by the JOBS Act and, as a result, will comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for emerging growth companies, which are the dates included below. In February 2015, the FASB issued Accounting Standards Update ("ASU") 2016-2, Leases (Topic 842), which amends the accounting guidance for leases and increases transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and requires disclosures of key information about leasing arrangements. ASU 2016-2 initially mandated a modified retrospective transition method, however, in July 2018, the FASB issued ASU 2018-11, Leases (Topic 842): Targeted Improvements, which amends ASU 2016-2, permitting entities the option to adopt this standard prospectively with a cumulative-effect adjustment to opening equity in the year of adoption and include required disclosures for prior periods but will not restate prior periods. The Company anticipates implementing the accounting guidance for leases using the alternative method beginning with the annual reporting period ending December 31, 2022 and interim reporting periods in 2023. The Company is in the process of evaluating the impact of adoption of the lease accounting guidance on the consolidated financial statements. In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses: Measurement of credit Losses on Financial Instruments (ASU 2016-13), which amends the impairment model by requiring entities to use a forward looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available-for-sale debt securities. The standard is effective for the company beginning in the first quarter of 2023, with early adoption permitted. the Company is currently evaluating the expected impact of ASU 2016-13 on its financial statements. In August 2020, the FASB issued ASU No. 2020-06, Debt - Debt with Conversion and other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity ("ASU 2020-06"), which simplifies accounting for convertible instruments by removing major seperation models required under current U.S. GAAP. ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exceptions and also simplifies the diluted earnings per share calculation in certain areas. The standard is effective for public business entities, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years and interim periods within those fiscal years, beginning December 15, 2021. For all other entities, the standard will be effective for fiscal years beginning after December 15, 2023. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, and adoption must be as of the beginning of the Company's annual fiscal year. The company is currently evaluating the impact of this standard on its consolidated financial statements and related disclosures.

Net Loss Per Share

6 Months Ended

Jun. 30, 2020

Earnings Per Share [Abstract]

Net Loss Per Share

Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and common share equivalents outstanding for the period. Common stock equivalents are only included when their effect is dilutive. The Company’s potentially dilutive securities which include outstanding stock options under the Company’s equity incentive plan have been excluded from the computation of diluted net loss per share as they would be anti-dilutive to the net loss per share. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position.

Potentially dilutive securities not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive are as follows (in common stock equivalent shares):


	June 30, 2020	June 30, 2019
Stock options	2,988,000	1,717,000
Warrants	79,914,000	4,224,000
Total	82,902,000	5,941,000

Revenue Recognition

6 Months Ended

Jun. 30, 2020

Revenue from Contract with Customer [Abstract]

Revenue Recognition

Revenue by Source


	Three Months Ended June 30,						Six Months Ended June 30,
	2020		2019		2020		2019
Instruments	$	229,000	$	1,591,000	$	763,000	$	2,892,000
Consumables	711,000		430,000		1,160,000		816,000
Total product revenue	940,000		2,021,000		1,923,000		3,708,000
Service and other	242,000		154,000		395,000		319,000
Total revenue	$	1,182,000	$	2,175,000	$	2,318,000	$	4,027,000

Revenue by Geographic Location


	Three Months Ended June 30,														Six Months Ended June 30,
	2020						2019						2020				2019
	$		%		$		%		$		%		$		%
North America	$	788,000	66	%	$	1,379,000	64	%	$	1,514,000	66	%	$	2,218,000	55	%
EMEIA	315,000		27	%	507,000		23	%	705,000		30	%	1,425,000		35	%
Asia Pacific	79,000		7	%	289,000		13	%	99,000		4	%	384,000		10	%
Total	$	1,182,000	100	%	$	2,175,000	100	%	$	2,318,000	100	%	$	4,027,000	100	%

The table above provides revenue from contracts with customers by business and geographic region on a disaggregated basis. North America consists of the United States and Canada. EMEIA consists of Europe, the Middle East, India and Africa. Asia

Pacific includes China, Japan, South Korea, Singapore and Australia. For the three months ended June 30, 2020 and 2019, the United States represented 60% and 63% of total revenue, and for the six months ended June 30, 2020 and 2019, 63% and 55%, respectively.

Remaining Performance Obligations

As of June 30, 2020, the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied was $373,000. These remaining performance obligations primarily relate to extended warranty and support and maintenance obligations. The Company expects to recognize approximately 44% of this amount as revenue during the remainder of 2020, 52% in 2021 and 4% in 2022. Warranty revenue is included in Service and other revenue.

The Company recognized revenue of $106,000 and $67,000 during the three months ended June 30, 2020 and 2019, respectively, and revenue of $232,000 and $156,000 during the six months ended June 30, 2020 and 2019, respectively, which was included in the contract liability balance at the end of the previous year.

Concentrations

As of June 30, 2020 and December 31, 2019, one customer represented 14% and 10%, respectively, of the Company's accounts receivable balance.

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI http://asc.fasb.org/topic&trid=49130388

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

+ Details

Balance Sheet Account Details

6 Months Ended

Jun. 30, 2020

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Balance Sheet Account Details


	June 30, 2020		December 31, 2019
Accounts receivable, net:
Accounts receivable, trade	$	5,094,000	$	6,889,000
Less allowance for doubtful accounts	(1,845,000)		(555,000)
	$	3,249,000	$	6,334,000

The Company extends credit to its customers in the normal course of business based upon an evaluation of each customer’s credit history, financial condition, and other factors. Estimates of allowances for doubtful accounts are determined by evaluating individual customer circumstances, historical payment patterns, length of time past due, and economic and other factors. During the three and six months ended June 30, 2020, the Company recorded bad debt expense of $332,000 and $1,290,000 respectively. These amounts are included in selling, general and administrative expenses.


	June 30, 2020		December 31, 2019
Inventory:
Materials and supplies	$	2,180,000	$	951,000
Finished goods	1,110,000		2,493,000
	$	3,290,000	$	3,444,000

Debt

6 Months Ended

Jun. 30, 2020

Debt Disclosure [Abstract]

Debt

Paycheck Protection Program

On April 17, 2020, the Company received loan proceeds of approximately $1.8 million (the “PPP Loan”) pursuant to the Paycheck Protection Program (“the PPP”) under the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) administered by the U.S. Small Business Administration (the “SBA”).

The PPP Loan is scheduled to mature on April 17, 2022 (the “Maturity Date”), bears interest at a rate of 1.00% per annum, and is subject to the standard terms and conditions applicable to loans administered by the SBA under the CARES Act.

The PPP Loan is evidenced by a promissory note, dated as of April 17, 2020, issued by East West Bank (the “PPP Lender”), which contains customary events of default relating to, among other things, payment defaults and breaches of representations and warranties. Upon an event of default under the PPP Note, the PPP Lender may, among other things, require immediate payment of all amounts owing under the PPP Note or file suit and obtain judgment. Under the terms of the CARES Act, recipients of loans under the PPP can apply for and be granted forgiveness for all or a portion of such loan granted under the PPP. Such forgiveness will be determined, subject to limitations, based on the use of loan proceeds for payment of payroll costs and certain other eligible costs (the “Eligible Costs”). Pursuant to the Paycheck Protection Program Flexibility Act (the “PPPFA”), enacted on June 5, 2020, the Company may continue to use loan proceeds on Eligible Costs through October 2, 2020, or the date that is 24 weeks from the PPP Loan origination date (the “Covered Period”). The Company is continuing to evaluate guidance released by the SBA regarding qualification for forgiveness of the PPP Loan, however, no assurance is provided that forgiveness for any portion of the Company’s PPP Loan will be obtained.

Under the PPPFA, payments of principal and interest due under the PPP Loan are deferred until the date on which the SBA remits the forgiveness amount, if any, back to the PPP Lender, or if forgiveness isn't sought within 10 months after the last day of the Covered Period, until the date that is 10 months from the last day of the Covered Period. The amounts outstanding under the PPP Loan may be prepaid by the Company at any time prior to maturity without penalty.

In order to apply for the PPP Loan, the Company was required to certify, among other things, that the current economic uncertainty made the PPP Loan request necessary to support the Company’s ongoing operations. This certification further required the Company to take into account the maintenance of its workforce, the Company’s need for additional funding to continue operations, and the Company’s ability to access alternative forms of capital in the current market environment to offset the effects of the COVID-19 pandemic.

Loan Agreements

The carrying value of the Company's debt for the periods presented was as follows:


	June 30, 2020		December 31, 2019
Term Loans	$	15,741,000	$	20,473,000
Revolver	—		1,498,000
PPP Loan	1,775,000		—
Total principal	17,516,000		21,971,000
Less unamortized debt issuance costs	(1,803,000)		(1,886,000)
Total carrying value of debt	$	15,713,000	$	20,085,000

In March 2019, the Company entered into a Loan and Security Agreement (the “Innovatus LSA”) by and among Innovatus Life Sciences Lending Fund I, LP, a Delaware limited partnership (“Innovatus”), as collateral agent and the lenders listed on Schedule 1.1 thereto, including East West Bank. The Innovatus LSA provided a first term loan of $17.5 million, a second term loan of $2.5 million and a third term loan of $5.0 million (collectively, “Term Loans”) if the Company satisfied certain funding conditions. Interest on the Term Loans is due on the first of each month at a rate of 10.25% per annum in cash or a discounted rate of 7.25% in cash with 3.0% of the 10.25% per annum rate added to the principal of the loan and subject to accruing interest through the end of the interest only payment period, which ends March 1, 2022. At inception, the Company elected to pay interest in cash at a rate of 7.25% per annum and have 3.0% per annum of the interest added back to the outstanding principal. As of June 30, 2020, the effective interest rate, including debt issuance costs, for Term Loans was 16.7%. Beginning in April 2022, the Company must make 24 equal monthly payments of principal and interest with a final maturity date in March 2024, which may be earlier due to an event of default if not cured within time specified.

The Innovatus LSA also provides for a revolving line of credit in an amount not to exceed $5.0 million (the “Revolver”). The Company may repay and reborrow amounts under the Revolver at any time prior to the March 1, 2024 maturity date without penalty or premium. The outstanding balance of amounts borrowed under the Revolver bears interest at a rate equal to 2.0% above the variable rate of interest, per annum, as specified in the terms of the Revolver.

The Innovatus LSA is collateralized by substantially all of the Company’s assets, including its intellectual property. The Innovatus LSA requires the Company to comply with various affirmative and negative covenants, including: (1) a liquidity covenant requiring the Company to maintain a minimum cash balance at all times in a collateral account; (2) a revenue

covenant requiring the Company to meet certain minimum revenue targets measured at the end of each calendar quarter. The Innovatus LSA also includes standard events of default, including a provision that Innovatus could declare an event of default upon the occurrence of any event that it interprets as having a material adverse change in the Company's business, operations, or condition, a material impairment on the Company's ability to pay the secured obligations under the Innovatus LSA, or upon a material adverse effect on the collateral under the agreement, thereby requiring us to repay the loan immediately, together with a prepayment fee and other applicable fees. As of June 30, 2020, the Company has not received any notification or indication from Innovatus to invoke the material adverse change clause. However, due to the Company’s current cash flow position and the substantial doubt about its ability to continue as a going concern, the entire principal amount of the Term Loans are presented as short-term. The Company will continue to evaluate the debt classification on a quarterly basis and evaluate for reclassification in the future should its financial condition improve.

As of December 31, 2019, the Company did not achieve certain financial covenants under the Innovatus LSA. As a result, in March 2020, the Company and Innovatus entered into an amendment to the Innovatus LSA (the “Second Amendment”) to, among other things: (i) waive the events of default from not achieving the specific financial covenants for the December 31, 2019 measurement date, (ii) require an immediate partial repayment of $2.1million, (iii) require an additional partial repayment of $2.9 million on the earlier of completion of an Equity Event (as defined in the Second Amendment), or April 30, 2020, (iv) modify the liquidity covenant, such that the Company’s minimum cash balance shall vary based on outstanding borrowing capacity under the Revolver (provided, however, that the Company shall maintain a minimum cash balance of $2 million at any given time), (v) reduce the dollar amount of certain minimum revenue covenants and (vi) modify the terms of certain events of default. For example, the Second Amendment provides for a cure period in connection with the breach of certain minimum revenue financial covenants, as long as the Company submits an updated management plan and financial projections, which are subject to Innovatus approval, and completes a Qualified Financing Event (as defined in the Second Amendment) within 45 days of such breach.

In connection with the Second Amendment, the Company was obligated to pay Innovatus a waiver fee in the amount of $200,000 and a prepayment fee of $100,000, payable in cash or in shares of the Company’s common stock at the Company's election, no later than following completion of the Equity Event. As described in Note 6 below, the Company completed the follow-on offering in April 2020 that constituted an Equity Event under the Second Amendment. A portion of the proceeds from the follow-on offering were used to pay-down $2.9 million of principal balance outstanding under the Innovatus term loan in accordance with the Second Amendment. In addition, the Company issued 872,601 shares of its common stock to Innovatus to satisfy the $200,000 waiver fee and $100,000 prepayment fee due under the Second Amendment.

The Company was in compliance with all financial covenants under the Innovatus LSA for the three months ended June 30, 2020.

Stockholders’ Equity and Stock-Based Compensation

6 Months Ended

Jun. 30, 2020

Share-based Payment Arrangement [Abstract]

Stockholders’ Equity and Stock-Based Compensation

Follow-on Public Offering

In April 2020, the Company completed an underwritten public offering of 16,896,000 shares of its common stock and, to certain investors, pre-funded warrants to purchase 37,650,000 shares of its common stock, and accompanying common warrants to purchase up to an aggregate of 54,546,000 shares of its common stock. Each share of common stock and pre-funded warrant to purchase one share of common stock was sold together with a common warrant to purchase one share of common stock. The public offering price of each share of common stock and accompanying common warrant was $0.33 and $0.329 for each pre-funded warrant. The pre-funded warrants are immediately exercisable at a price of $0.001 per share of common stock. The common warrants are immediately exercisable at a price of $0.33 per share of common stock and will expire five years from the date of issuance. The shares of common stock and pre-funded warrants, and the accompanying common warrants, were issued separately and were immediately separable upon issuance. The gross proceeds to the Company were approximately $18.0 million before deducting underwriting discounts and commissions and other offering expenses.

Stock Warrants

A summary of the Company’s warrant activity for the six months ended June 30, 2020 was as follows:


	Shares of Stock under Warrants	Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term	Aggregate Intrinsic Value
Outstanding at January 1, 2020	24,406,000	$	1.76	4.82	$	7,933,000
Granted	95,396,000	0.22		4.78
Exercised	(39,888,000)	0.09			15,863,000
Canceled	—
Outstanding at June 30, 2020	79,914,000	$	0.76	4.62	$	18,232,000
Vested and exercisable at June 30, 2020	79,914,000	$	0.76	4.62	$	—

Warrant Exercise Update

From July 1, 2020 through August 12, 2020, the Company has received gross proceeds of approximately $13.9 million pursuant to the exercise of outstanding and common and pre-funded warrants to purchase an aggregate of 46,505,000 shares of the Company's common stock.

Warrant Inducement

As previously reported, the Company issued warrants (the “Original Warrants”) to purchase shares of the Company’s Common Stock to certain investors in the Company’s underwritten public offering completed on October 23, 2019. The Original Warrants were immediately exercisable upon issuance at an exercise price per share of $0.86 and are set to expire on October 23, 2024.

On March 2, 2020, the Company entered into a Warrants Amendment and Agreement (the “Inducement Agreement”) with certain holders (“Holders”) of the Original Warrants that are exercisable for an aggregate of up to 3,200,000 shares of Common Stock. The Inducement Agreement provided that, commencing immediately following the delivery to the Holders of a prospectus supplement (the “Prospectus Supplement”) relating to the impact of the Inducement Agreement on the Original Warrants and ending at 9:15 a.m. Eastern Time on the business day following the date of such delivery (the “Modified Exercise Price Term”), the exercise price per share for the Original Warrants will be equal to $0.75 but only with respect to a cash exercise under Section 1(a) of the Original Warrants. In addition, the Company and each Holder agreed that if and only if the Holders exercise for cash all of their Original Warrants as amended pursuant to the Inducement Agreement during the Modified Exercise Price Term, the Company will issue to each Holder a new warrant (collectively, the “New Warrants”) to purchase up to the same number of shares of Common Stock issued to such Holder pursuant to the exercise of its Original Warrant during the Modified Exercise Price Term.

The Company delivered the Prospectus Supplement on March 2, 2020 and each Holder exercised all of their Original Warrants for cash. As a result, on March 3, 2020, the Company issued the New Warrants to the Holders. The New Warrants are exercisable at an exercise price per share of $1.06 commencing on the six-month anniversary of the issuance date, and will terminate on the date that is five years, six months following the issuance date. The New Warrants and the shares of Common Stock issuable upon exercise of the New Warrants were not registered under the Securities Act of 1933, as amended (the "Securities Act"), and were offered pursuant to the exemption provided in Section 4(a)(2) under the Securities Act.

Stock-Based Compensation

Stock Options

A summary of the Company’s stock option activity for the six months ended June 30, 2020 was as follows:


	Shares of Stock under Stock Options	Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term	Aggregate Intrinsic Value
Outstanding at January 1, 2020	1,743,000	$	5.73	8.2	$	4,000
Granted	1,591,000	0.88
Exercised	—	—			$	—
Canceled	(346,000)	4.04
Outstanding at June 30, 2020	2,988,000	$	3.34	8.46	$	22,000
Vested and exercisable at June 30, 2020	1,021,000	$	5.65	6.93	$	—

For the three months ended June 30, 2020 and 2019, the Company granted to its employees options to purchase 443,000 and 42,000 shares with a weighted average exercise price of $0.46 and $3.00 per share, respectively. For the six months ended June 30, 2020 and 2019, the Company granted to its employees options to purchase 1,591,000 and 545,000 shares with a weighted average exercise price of $0.88 and $4.15 per share, respectively.

For the three months ended June 30, 2020 and 2019, the weighted-average grant date fair value of stock options granted was $0.30 and $1.71 per share, respectively. For the six months ended June 30, 2020 and 2019, the weighted-average grant date fair value of stock options granted was $0.55 and $2.37 per share, respectively.

The Company recognized stock-based compensation expense for the periods presented were as follows:


	Three Months Ended June 30,									Six Months Ended June 30,
			2020			2019			2020			2019
Research and development	$	66,000		$	58,000		$	133,000		$	111,000
General and administrative	262,000			278,000			523,000			514,000
Total stock-based compensation expense	$	328,000		$	336,000		$	656,000		$	625,000

The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the employee stock option grants during the periods presented were as follows:


	Three Months Ended June 30,									Six Months Ended June 30,
			2020			2019			2020			2019
Risk-free interest rate	0.4	%		2.0	%		1.1	%		2.4	%
Expected volatility	77.9	%		66.1	%		72.2	%		67.3	%
Expected term (in years)	5.5			5.4			5.9			5.0
Expected dividend yield	0.0	%		0.0	%		0.0	%		0.0	%

Legal Proceedings	6 Months Ended
Legal Proceedings	Jun. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Legal Proceedings	Legal ProceedingsThe Company is subject to potential liabilities under various claims and legal actions that are pending or may be asserted. These matters arise in the ordinary course and conduct of the business. The Company intends to continue to defend itself vigorously in such matters. The Company regularly assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in the financial statements. An estimated loss contingency is accrued in the financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Based on the Company’s assessment, it currently does not have any amount accrued as it is not a defendant in any claims or legal actions.

Income Taxes	6 Months Ended
Income Taxes	Jun. 30, 2020
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The Company is subject to taxation in the United States, United Kingdom and various state jurisdictions. The Company computes its quarterly income tax provision by using a forecasted annual effective tax rate and adjusts for any discrete items arising during the quarter. The primary difference between the effective tax rate and the federal statutory tax rate relates to the full valuation allowance on the Company's U.S. net operating losses.In response to the COVID-19 pandemic, the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”) was signed into law on March 27, 2020. The CARES Act, among other things, includes tax provisions relating to refundable payroll tax credits, deferment of employer’s social security payments, net operating loss utilization and carryback periods, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property (QIP). The CARES Act did not have a material impact on the Company’s income tax provision for the three months ended June 30, 2020. The Company continues to evaluate the impact of the CARES Act on its financial position, results of operations and cash flows.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References + Details

Organization and Basis of Presentation (Policies)	6 Months Ended
Organization and Basis of Presentation (Policies)	Jun. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation The accompanying financial information has been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission for interim reporting purposes. The condensed consolidated financial statements are unaudited. The unaudited condensed consolidated financial statements reflect, in the opinion of the Company's management, all adjustments, consisting of only normal recurring adjustments, necessary for a fair presentation of financial position, results of operations, changes in equity, and comprehensive loss and cash flows for each period presented in accordance with United States generally accepted accounting principles (“U.S. GAAP”). All intercompany transactions and balances have been eliminated. These interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2019. Certain prior year numbers were reclassified to conform with current year presentation. Such reclassification had no impact on the previously reported results of operations.
Recently Issued But Not Yet Adopted Accounting Pronouncements	Recently Issued But Not Yet Adopted Accounting Pronouncements In April 2012, the Jump-Start Our Business Startups Act (the “JOBS Act”) was signed into law. The JOBS Act contains provisions that, among other things, reduce certain reporting requirements for an emerging growth company. As an emerging growth company, the Company may elect to adopt new or revised accounting standards when they become effective for non-public companies, which typically is later than when public companies must adopt the standards. The Company has elected to take advantage of the extended transition period afforded by the JOBS Act and, as a result, will comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for emerging growth companies, which are the dates included below. In February 2015, the FASB issued Accounting Standards Update ("ASU") 2016-2, Leases (Topic 842), which amends the accounting guidance for leases and increases transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and requires disclosures of key information about leasing arrangements. ASU 2016-2 initially mandated a modified retrospective transition method, however, in July 2018, the FASB issued ASU 2018-11, Leases (Topic 842): Targeted Improvements, which amends ASU 2016-2, permitting entities the option to adopt this standard prospectively with a cumulative-effect adjustment to opening equity in the year of adoption and include required disclosures for prior periods but will not restate prior periods. The Company anticipates implementing the accounting guidance for leases using the alternative method beginning with the annual reporting period ending December 31, 2022 and interim reporting periods in 2023. The Company is in the process of evaluating the impact of adoption of the lease accounting guidance on the consolidated financial statements. In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses: Measurement of credit Losses on Financial Instruments (ASU 2016-13), which amends the impairment model by requiring entities to use a forward looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available-for-sale debt securities. The standard is effective for the company beginning in the first quarter of 2023, with early adoption permitted. the Company is currently evaluating the expected impact of ASU 2016-13 on its financial statements. In August 2020, the FASB issued ASU No. 2020-06, Debt - Debt with Conversion and other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity ("ASU 2020-06"), which simplifies accounting for convertible instruments by removing major seperation models required under current U.S. GAAP. ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exceptions and also simplifies the diluted earnings per share calculation in certain areas. The standard is effective for public business entities, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years and interim periods within those fiscal years, beginning December 15, 2021. For all other entities, the standard will be effective for fiscal years beginning after December 15, 2023. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, and adoption must be as of the beginning of the Company's annual fiscal year. The company is currently evaluating the impact of this standard on its consolidated financial statements and related disclosures.
Net Loss Per Share	Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and common share equivalents outstanding for the period. Common stock equivalents are only included when their effect is dilutive. The Company’s potentially dilutive securities which include outstanding stock options under the Company’s equity incentive plan have been excluded from the computation of diluted net loss per share as they would be anti-dilutive to the net loss per share. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position.

Net Loss Per Share (Tables)

6 Months Ended

Jun. 30, 2020

Earnings Per Share [Abstract]

Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss Per Share Attributable to Common Stockholders


	June 30, 2020	June 30, 2019
Stock options	2,988,000	1,717,000
Warrants	79,914,000	4,224,000
Total	82,902,000	5,941,000

Revenue Recognition (Tables)

6 Months Ended

Jun. 30, 2020

Revenue from Contract with Customer [Abstract]

Schedule of Revenue Recognition

Revenue by Source


	Three Months Ended June 30,						Six Months Ended June 30,
	2020		2019		2020		2019
Instruments	$	229,000	$	1,591,000	$	763,000	$	2,892,000
Consumables	711,000		430,000		1,160,000		816,000
Total product revenue	940,000		2,021,000		1,923,000		3,708,000
Service and other	242,000		154,000		395,000		319,000
Total revenue	$	1,182,000	$	2,175,000	$	2,318,000	$	4,027,000

Revenue by Geographic Location


	Three Months Ended June 30,														Six Months Ended June 30,
	2020						2019						2020				2019
	$		%		$		%		$		%		$		%
North America	$	788,000	66	%	$	1,379,000	64	%	$	1,514,000	66	%	$	2,218,000	55	%
EMEIA	315,000		27	%	507,000		23	%	705,000		30	%	1,425,000		35	%
Asia Pacific	79,000		7	%	289,000		13	%	99,000		4	%	384,000		10	%
Total	$	1,182,000	100	%	$	2,175,000	100	%	$	2,318,000	100	%	$	4,027,000	100	%

Balance Sheet Account Details (Tables)

6 Months Ended

Jun. 30, 2020

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of Accounts Receivable


	June 30, 2020		December 31, 2019
Accounts receivable, net:
Accounts receivable, trade	$	5,094,000	$	6,889,000
Less allowance for doubtful accounts	(1,845,000)		(555,000)
	$	3,249,000	$	6,334,000

Schedule of Components of Inventories


	June 30, 2020		December 31, 2019
Inventory:
Materials and supplies	$	2,180,000	$	951,000
Finished goods	1,110,000		2,493,000
	$	3,290,000	$	3,444,000

Debt (Tables)

6 Months Ended

Jun. 30, 2020

Debt Disclosure [Abstract]

Schedule of Debt

The carrying value of the Company's debt for the periods presented was as follows:


	June 30, 2020		December 31, 2019
Term Loans	$	15,741,000	$	20,473,000
Revolver	—		1,498,000
PPP Loan	1,775,000		—
Total principal	17,516,000		21,971,000
Less unamortized debt issuance costs	(1,803,000)		(1,886,000)
Total carrying value of debt	$	15,713,000	$	20,085,000

Stockholders’ Equity and Stock-Based Compensation (Tables)

6 Months Ended

Jun. 30, 2020

Share-based Payment Arrangement [Abstract]

Schedule of Warrant Activity

A summary of the Company’s warrant activity for the six months ended June 30, 2020 was as follows:


	Shares of Stock under Warrants	Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term	Aggregate Intrinsic Value
Outstanding at January 1, 2020	24,406,000	$	1.76	4.82	$	7,933,000
Granted	95,396,000	0.22		4.78
Exercised	(39,888,000)	0.09			15,863,000
Canceled	—
Outstanding at June 30, 2020	79,914,000	$	0.76	4.62	$	18,232,000
Vested and exercisable at June 30, 2020	79,914,000	$	0.76	4.62	$	—

Summary of Stock Option Activity

A summary of the Company’s stock option activity for the six months ended June 30, 2020 was as follows:


	Shares of Stock under Stock Options	Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term	Aggregate Intrinsic Value
Outstanding at January 1, 2020	1,743,000	$	5.73	8.2	$	4,000
Granted	1,591,000	0.88
Exercised	—	—			$	—
Canceled	(346,000)	4.04
Outstanding at June 30, 2020	2,988,000	$	3.34	8.46	$	22,000
Vested and exercisable at June 30, 2020	1,021,000	$	5.65	6.93	$	—

Summary of Recognized Stock-Based Compensation Expense

The Company recognized stock-based compensation expense for the periods presented were as follows:


	Three Months Ended June 30,									Six Months Ended June 30,
			2020			2019			2020			2019
Research and development	$	66,000		$	58,000		$	133,000		$	111,000
General and administrative	262,000			278,000			523,000			514,000
Total stock-based compensation expense	$	328,000		$	336,000		$	656,000		$	625,000

Schedule of Weighted-Average Assumptions in Black -Scholes Option Pricing Model

The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the employee stock option grants during the periods presented were as follows:


	Three Months Ended June 30,									Six Months Ended June 30,
			2020			2019			2020			2019
Risk-free interest rate	0.4	%		2.0	%		1.1	%		2.4	%
Expected volatility	77.9	%		66.1	%		72.2	%		67.3	%
Expected term (in years)	5.5			5.4			5.9			5.0
Expected dividend yield	0.0	%		0.0	%		0.0	%		0.0	%

Organization and Basis of Presentation (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit	$ (121,161)	$ (102,577)
Cash and cash equivalents	$ 17,194	$ 17,311

Net Loss Per Share (Details) - shares shares in Thousands	6 Months Ended
Net Loss Per Share (Details) - shares shares in Thousands	Jun. 30, 2020	Jun. 30, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount (in shares)	82,902	5,941
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount (in shares)	2,988	1,717
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount (in shares)	79,914	4,224

Revenue Recognition - Revenue by Source and Geographic Location (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Disaggregation of Revenue [Line Items]
Revenue	$ 1,182	$ 2,175	$ 2,318	$ 4,027
North America
Disaggregation of Revenue [Line Items]
Revenue	788	1,379	1,514	2,218
EMEIA
Disaggregation of Revenue [Line Items]
Revenue	315	507	705	1,425
Asia Pacific
Disaggregation of Revenue [Line Items]
Revenue	$ 79	$ 289	$ 99	$ 384
Revenue from Contract with Customer \| Geographic Concentration Risk
Disaggregation of Revenue [Line Items]
Concentration risk percentage	100.00%	100.00%	100.00%	100.00%
Revenue from Contract with Customer \| Geographic Concentration Risk \| North America
Disaggregation of Revenue [Line Items]
Concentration risk percentage	66.00%	64.00%	66.00%	55.00%
Revenue from Contract with Customer \| Geographic Concentration Risk \| EMEIA
Disaggregation of Revenue [Line Items]
Concentration risk percentage	27.00%	23.00%	30.00%	35.00%
Revenue from Contract with Customer \| Geographic Concentration Risk \| Asia Pacific
Disaggregation of Revenue [Line Items]
Concentration risk percentage	7.00%	13.00%	4.00%	10.00%
Instruments
Disaggregation of Revenue [Line Items]
Revenue	$ 229	$ 1,591	$ 763	$ 2,892
Consumables
Disaggregation of Revenue [Line Items]
Revenue	711	430	1,160	816
Product revenue
Disaggregation of Revenue [Line Items]
Revenue	940	2,021	1,923	3,708
Service and other revenue
Disaggregation of Revenue [Line Items]
Revenue	$ 242	$ 154	$ 395	$ 319

Revenue Recognition - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Disaggregation of Revenue [Line Items]
Performance obligation	$ 373		$ 373
Revenue recognized	$ 106	$ 67	$ 232	$ 156
Geographic Concentration Risk \| Revenue Benchmark \| United States
Disaggregation of Revenue [Line Items]
Concentration risk percentage	60.00%	63.00%	63.00%	55.00%
Customer Concentration Risk \| Accounts Receivable \| Largest Customer
Disaggregation of Revenue [Line Items]
Concentration risk percentage			14.00%		10.00%

Revenue Recognition - Remaining Performance Obligations (Details)	Jun. 30, 2020
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-07-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligation, percentage	44.00%
Expected timing of satisfaction	6 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligation, percentage	52.00%
Expected timing of satisfaction	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligation, percentage	4.00%
Expected timing of satisfaction	1 year

Balance Sheet Account Details - Schedule of Accounts Receivable (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accounts receivable, trade	$ 5,094	$ 5,094		$ 6,889
Less allowance for doubtful accounts	(1,845)	(1,845)		(555)
Accounts receivable, net	3,249	3,249		$ 6,334
Provision for bad debt expense	$ 332	$ 1,290	$ 0

Balance Sheet Account Details - Schedule of Components of Inventories (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Materials and supplies	$ 2,180	$ 951
Finished goods	1,110	2,493
Finished goods	$ 3,290	$ 3,444

Debt - Narrative (Details)		1 Months Ended
Debt - Narrative (Details)	Apr. 17, 2020 USD ($)	Apr. 30, 2020 USD ($) shares	Dec. 31, 2019 USD ($)	Mar. 31, 2019 USD ($)	Jun. 30, 2020 payment
The Loan \| Unsecured Loan
Debt Instrument [Line Items]
Proceeds from issuance of debt	$ 1,800,000
Debt percentage	1.00%
Term A-1 Loan
Debt Instrument [Line Items]
Term loan face value				$ 17,500,000
Term A-2 Loan
Debt Instrument [Line Items]
Term loan face value				$ 2,500,000
Innovatus LSA
Debt Instrument [Line Items]
Debt percentage				3.00%
Term loan face value				$ 5,000,000.0
Cash rate				10.25%
Discounted cash rate				7.25%
Effective interest rate					16.70%
Number of monthly payments \| payment					24
Repayments of debt			$ 2,100,000
Default payment required upon completion of equity raise		$ 2,900,000	2,900,000
Minimum cash balance			$ 2,000,000
Waiver fee payment period			45 days
Waiver fee		200,000	$ 200,000
Prepayment fee		$ 100,000	$ 100,000
Warrants to purchase shares issued (in shares) \| shares		872,601
Innovatus LSA \| PIK
Debt Instrument [Line Items]
Cash rate				3.00%
Revolver
Debt Instrument [Line Items]
Term loan facility available				$ 5,000,000.0
Prepayment fee percentage				2.00%

Debt - Schedule of Debt (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Total principal	$ 17,516	$ 21,971
Less unamortized debt issuance costs	(1,803)	(1,886)
Total carrying value of debt	15,713	20,085
Term Loans
Debt Instrument [Line Items]
Total principal	15,741	20,473
Revolver
Debt Instrument [Line Items]
Total principal	0	1,498
PPP Loan
Debt Instrument [Line Items]
Total principal	$ 1,775	$ 0

Stockholders’ Equity and Stock-Based Compensation - Follow-on Public Offering Narrative (Details) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended
	Apr. 30, 2020	Jun. 30, 2020	Mar. 03, 2020	Mar. 02, 2020	Dec. 31, 2019	Oct. 23, 2019
Class of Stock [Line Items]
Warrants to purchase shares (in shares)				3,200,000
Warrants exercise price (in USD per share)		$ 0.76	$ 1.06	$ 0.75	$ 1.76	$ 0.86
Gross proceeds	$ 18.0
Common Warrants
Class of Stock [Line Items]
Number of securities called by each warrant (in shares)	1
Price per share (in USD per share)	$ 0.33
Warrants exercise price (in USD per share)	$ 0.33
Class of warrant or right, expiration period (in years)	5 years
Pre-Funded Warrant
Class of Stock [Line Items]
Number of securities called by each warrant (in shares)	1
Price per share (in USD per share)	$ 0.329
Warrants exercise price (in USD per share)	$ 0.001
Common Stock
Class of Stock [Line Items]
Number of shares issued (in shares)	16,896,000
Common Stock \| Common Warrants
Class of Stock [Line Items]
Warrants to purchase shares (in shares)	54,546,000
Common Stock \| Pre-Funded Warrant
Class of Stock [Line Items]
Warrants to purchase shares (in shares)	37,650,000

Stockholders’ Equity and Stock-Based Compensation - Warrant Activity (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Shares of Stock under Warrants
Beginning balance (in shares)	24,406
Granted (in shares)	95,396
Exercised (in shares)	(39,888)
Canceled (in shares)	0
Ending balance (in shares)	79,914	24,406
Vested and exercisable (in shares)	79,914
Weighted- Average Exercise Price
Beginning balance (in USD per share)	$ 1.76
Granted (in USD per share)	0.22
Exercised (in USD per share)	0.09
Ending balance (in USD per share)	0.76	$ 1.76
Vested and exercisable (in USD per share)	$ 0.76
Weighted- Average Remaining Contractual Term
Balance	4 years 7 months 13 days	4 years 9 months 25 days
Granted	4 years 9 months 10 days
Vested and exercisable	4 years 7 months 13 days
Aggregate Intrinsic Value
Beginning balance	$ 7,933
Exercised	15,863
Ending balance	18,232	$ 7,933
Vested and exercisable	$ 0

Stockholders’ Equity and Stock-Based Compensation - Warrant Exercise Update and Inducement (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions		1 Months Ended
	Mar. 03, 2020	Aug. 12, 2020	Apr. 30, 2020	Jun. 30, 2020	Mar. 02, 2020	Dec. 31, 2019	Oct. 23, 2019
Class of Warrant or Right [Line Items]
Gross proceeds			$ 18.0
Warrants to purchase shares (in shares)					3,200
Warrants exercise price (in USD per share)	$ 1.06			$ 0.76	$ 0.75	$ 1.76	$ 0.86
Class of warrant or right exercisable term	6 months
Termination term	5 years 6 months
Subsequent Event
Class of Warrant or Right [Line Items]
Gross proceeds		$ 13.9
Warrants to purchase shares (in shares)		46,505

Stockholders’ Equity and Stock-Based Compensation - Summary of Stock Option Activity (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Shares of Stock under Stock Options
Beginning balance (in shares)			1,743
Granted (in shares)	443	42	1,591	545
Exercised (in shares)			0
Canceled (in shares)			(346)
Ending balance (in shares)	2,988		2,988		1,743
Vested and exercisable (in shares)	1,021		1,021
Weighted- Average Exercise Price
Beginning balance (in USD per share)			$ 5.73
Granted (in USD per share)	$ 0.46	$ 3.00	0.88	$ 4.15
Exercised (in USD per share)			0
Canceled (in USD per share)			4.04
Ending balance (in USD per share)	3.34		3.34		$ 5.73
Vested and exercisable (in USD per share)	$ 5.65		$ 5.65
Weighted- Average Remaining Contractual Term
Outstanding (in years)			8 years 5 months 15 days		8 years 2 months 12 days
Vested and exercisable (in years)			6 years 11 months 4 days
Aggregate Intrinsic Value
Beginning balance			$ 4
Exercised			0
Ending balance	$ 22		22		$ 4
Vested and exercisable	$ 0		$ 0
Weighted-average grant date fair value (in USD per share)	$ 0.30	$ 1.71	$ 0.55	$ 2.37

Stockholders’ Equity and Stock-Based Compensation - Recognized Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
General and administrative	$ 328	$ 336	$ 656	$ 625
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
General and administrative	66	58	133	111
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
General and administrative	$ 262	$ 278	$ 523	$ 514

Stockholders’ Equity and Stock-Based Compensation - Assumptions (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Share-based Payment Arrangement [Abstract]
Risk-free interest rate	0.40%	2.00%	1.10%	2.40%
Expected volatility (as a percent)	77.90%	66.10%	72.20%	67.30%
Expected term (in years)	5 years 6 months	5 years 4 months 24 days	5 years 10 months 24 days	5 years
Expected dividend yield (as a percent)	0.00%	0.00%	0.00%	0.00%